

FRANCESCO GROSSI

CURRICULUM VITAE

Dati personali

Cognome: Grossi
Nome: Francesco

Data di nascita: 10 Ottobre 1965
Luogo di nascita: Genova
Codice fiscale: GRSFNC65R10D969W

Cittadinanza: Italiana
Stato civile: Coniugato, 1 figlio

Indirizzo casa: ~~Via Assonico 18/10~~
16122 Genova
~~CAP 16122~~

Indirizzo ospedale: UOC Oncologia Medica
Fondazione IRCCS Cà Granda
Ospedale Maggiore Policlinico
Via della Commenda, 19
20122 Milano
Tel: 0255032556

E-mail: francesco.grossi@policlinico.mi.it

Formazione

2018 Conseguimento dell'Abilitazione Scientifica Nazionale a professore prima fascia (sette concorsuale malattie del sangue, oncologia e reumatologia), Ministero dell'Istruzione, dell'Università e della Ricerca Scientifica

2013 Conseguimento dell'Abilitazione Scientifica Nazionale a professore associato (sette concorsuale malattie del sangue, oncologia e reumatologia), Ministero dell'Istruzione, dell'Università e della Ricerca Scientifica

24/11/11 Superamento del corso: "Ippocrate: Competenze di management per i medici dirigenti" Scuola di Direzione Aziendale (SDA), Università L. Bocconi Milano.

30/10/97 Specialità in Oncologia indirizzo Oncologia Medica (50/50 e lode). Università degli Studi di Genova.

30/11/92 Esame di Stato per l'abilitazione alla professione medica (90/90). Università degli Studi di Genova.

20/10/92 Laurea in Medicina e Chirurgia (110/110 e lode). Università degli Studi di Genova.

Esperienze professionali

dal 01/09/2018 Direttore UOC Oncologia Medica presso Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano.

2010-31/08/2018 Responsabile UOS Tumori Polmonari presso IRCCS AOU San Martino – IST Istituto Nazionale per la Ricerca sul Cancro (ora Ospedale Policlinico San Martino), Genova.

2009 - 2011 Membro del Comitato Tecnico Scientifico (CTS). Istituto Nazionale per la Ricerca sul Cancro di Genova.

2007- 2018 Coordinatore del Disease Management Team (DMT) sulle neoplasie toraciche. Istituto Nazionale per la Ricerca sul Cancro (ora Ospedale Policlinico San Martino), Genova.

- 2003-2010 Dirigente Medico presso S.C. Oncologia Medica A. Istituto Nazionale per la Ricerca sul Cancro, Genova. Dal 2010 con incarico Responsabile di UOS Tumori Polmonari
- 1999-2003 Dirigente Medico presso Clinica Oncologica, Policlinico Universitario, Azienda Ospedaliera Santa Maria della Misericordia di Udine.
- 1999 Dirigente Sanitario a tempo pieno e determinato. Clinica Oncologica, Policlinico Universitario, Azienda Ospedaliera Santa Maria della Misericordia di Udine.
- 1997-1998 Contrattista ricercatore ai sensi dell'art. 36 del DPR 617/80 in Oncologia Medica. Istituto Nazionale per la Ricerca sul Cancro, Genova.
- 1993 - 1997 Specializzando Oncologia Medica. Università degli Studi di Genova. (con aspettativa per servizio di leva art. 67 D.P.R. 10/1/57 n. 3 dal 14/3/1993 al 13/7/1994 - Corso Allievi ufficiali di Complemento - Scuola di Sanità, Accademia Navale di Livorno - Capo Servizio Sanitario, Maridrografico Genova)

Attività Accademica

- 2011- 2018 Professore a contratto ex art. 23, L.240/2010 nella Scuola di Specializzazione in Oncologia Medica – Università degli Studi di Genova.
- 2017-2018 Membro del Collegio dei Docenti del Dottorato di Ricerca in “Emato-oncologia e Medicina Interna Clinico-Traslazionale”. Università degli Studi di Genova.
- 2015-2018 Professore a contratto ex art. 23, L.240/2010 nel Corso di laurea in Medicina e Chirurgia – Università degli Studi di Genova.
- 2013-2015 Lezioni seminariali nel Corso di laurea magistrale in Medicina e Chirurgia per l’insegnamento di “Oncologia Medica”. Università degli Studi di Genova.
- 2012-2015 Lezioni seminariali nella Scuola di Specializzazione in Farmacia Ospedaliera, Dipartimento di Farmacia. Università degli Studi di Genova.
- 2008-2011 Lezioni seminariali nella Scuola di Specializzazione in Oncologia Medica negli aa.aa 2008/2009, 2009/2010, 2010/2011. Università degli Studi di Genova.
- 2005 - 2011 Professore a contratto nella Scuola di Specializzazione in Chirurgia Toracica – Università degli Studi di Genova.

Premi e riconoscimenti per l'attività scientifica

- 1997 ASCO Merit Award, American Society of Clinical Oncology.
- 1997 AIOM Premio per il contributo meritevole, Associazione Italiana di Oncologia Medica.

Altri incarichi

- 2008-2012 Membro della Commissione Nazionale sulla Prevenzione Oncologica. Ministero del Lavoro, della Salute e delle Politiche Sociali.

Articoli indicizzati in PubMed

1. Wang C, Xu F, Shen J, Zhang L, Zhang J, Jin J, Ampollini L, van Schil P, Kimura H, **Grossi F**, Suda K, Zhang B, Ma D; written on behalf of the AME Lung Cancer Collaborative Group.
Successful treatment of lung adenocarcinoma with gefitinib based on *EGFR* gene amplification.

J Thorac Dis. 2018 Nov;10(11):E779-E783

2. Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, **Grossi F**, Chiari R.
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
J Cancer Res Clin Oncol. 2018 Dec 1. [Epub ahead of print]
3. Tagliamento M, Genova C, Rijavec E, Rossi G, Biello F, Dal Bello MG, Alama A, Coco S, Boccardo S, **Grossi F**.
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.
Expert Opin Pharmacother. 2018 Nov 3:1-8. [Epub ahead of print]
4. Rossi G, Alama A, Genova C, Rijavec E, Tagliamento M, Biello F, Coco S, Dal Bello MG, Boccardo S, **Grossi F**.
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer.
Expert Opin Pharmacother. 2018 Oct 24:1-8. [Epub ahead of print]
5. Barbone F, Barbiero F, Belvedere O, Rosolen V, Giangreco M, Zanin T, Pisa FE, Meduri S, Follador A, **Grossi F**, Fasola G.
Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers.
Int J Epidemiol. 2018 Oct 15. [Epub ahead of print]
6. Gridelli C, de Castro Carpeno J, Dingemans AC, Griesinger F, **Grossi F**, Langer C, Ohe Y, Syrigos K, Thatcher N, Das-Gupta A, Truman M, Donica M, Smoljanovic V, Bennouna J.
Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.
JAMA Oncol. 2018 Aug 30:e183486. doi: 10.1001/jamaoncol.2018.3486. [Epub ahead of print]
7. Gregorc V, Cavina R, Novello S, **Grossi F**, Lazzari C, Capelletto E, Genova C, Salini G, Lambiase A, Santoro A.
NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer.
Oncologist. 2018 Aug 3. pii: theoncologist.2018-0292. doi: 10.1634/theoncologist.2018-0292. [Epub ahead of print]
8. **Grossi F**, Crinò L, Logroscino A, Canova S, Delmonte A, Melotti B, Proto C, Gelibter A, Cappuzzo F, Turci D, Gamucci T, Antonelli P, Marchetti P, Santoro A, Giusti S, Di Costanzo F, Giustini L, Del Conte A, Livi L, Giannarelli D, de Marinis F.
Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.
Eur J Cancer. 2018 Sep;100:126-134. doi: 10.1016/j.ejca.2018.05.015. Epub 2018 Jul 13.
9. Gridelli C, Ascierto PA, **Grossi F**, Baldini E, Favaretto A, Garassino MC, Morabito A, Migliorino MR, Rossi A, de Marinis F.
Second-line treatment of advanced non-small cell lung cancer non-oncogene addicted: new treatment algorithm in the era of novel immunotherapy.
Curr Clin Pharmacol. 2018 Jul 11. doi: 10.2174/1574884713666180711160008. [Epub ahead of print]
10. Fasola G, De Carlo E, **Grossi F**.
[Checkpoint inhibitors in the decision-making algorithm of advanced non-small-cell lung cancer.]
Recenti Prog Med. 2018 Jun;109(6):328-332. doi: 10.1701/2932.29487. Italian.
11. de Marinis F, Ciardiello F, Baas P, Crinò L, Giaccone G, **Grossi F**, Hellmann MD, Mok TSK, Lena H, Paz-Ares L, Rodriguez-Abreu D, Von Pavel J, Gridelli C.
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT).
ESMO Open. 2018 May 31;3(4):e000298. doi: 10.1136/esmoopen-2017-000298. eCollection 2018. Review.
12. Tagliamento M, Rijavec E, Barletta G, Biello F, Rossi G, **Grossi F**, Genova C.

- CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.
Expert Opin Biol Ther. 2018 Jul;18(7):829-835. doi: 10.1080/14712598.2018.1492539. Epub 2018 Jul 4.
13. Gregorc V, Gaafar RM, Favaretto A, **Grossi F**, Jassem J, Polychronis A, Bidoli P, Tiseo M, Shah R, Taylor P, Novello S, Muzio A, Bearz A, Greillier L, Fontana F, Salini G, Lambiase A, O'Brien M.
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol. 2018 Jun;19(6):799-811. doi: 10.1016/S1470-2045(18)30193-1. Epub 2018 May 9.
 14. Garassino MC, Gelibter AJ, **Grossi F**, Chiari R, Soto Parra H, Cascinu S, Cognetti F, Turci D, Blasi L, Bengala C, Mini E, Baldini E, Quadrini S, Ceresoli GL, Antonelli P, Vasile E, Pinto C, Fasola G, Galetta D, Macerelli M, Giannarelli D, Lo Russo G, de Marinis F.
Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients.
J Thorac Oncol. 2018 Aug;13(8):1146-1155. doi: 10.1016/j.jtho.2018.04.025. Epub 2018 May 3.
 15. Leena Gandhi, Delvys Rodríguez Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J. Hochmair, Steven F. Powell, Susanna Yee-Shan Cheng, Helge G. Bischoff, Nir Peled, **Francesco Grossi**, Ross R. Jennens, Martin Reck, Rina Hui, Edward B. Garon, Michael Boyer, Belén Rubio-Viqueira, Silvia Novello, Takayasu Kurata, Jhanelle E. Gray, John Vida, Ziwen Wei, Jing Yang, Harry Raftopoulos, M. Catherine Pietanza, Marina C. Garassino, for the KEYNOTE-189 Investigators
Pembrolizumab-Pemetrexed-Platinum for Metastatic Non-Small-Cell Lung Cancer
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
 16. Sarocchi M, **Grossi F**, Arboscello E, Bellodi A, Genova C, Dal Bello MG, Rijavec E, Barletta G, Rossi G, Biello F, Ghigliotti G, Canepa M, Mussap M, Brunelli C, Spallarossa P.
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
Oncologist. 2018 Aug;23(8):936-942. doi: 10.1634/theoncologist.2017-0452. Epub 2018 Mar 22.
 17. **Grossi F**, Genova C, Rijavec E, Barletta G, Biello F, Dal Bello MG, Meyer K, Roder J, Roder H, Grigorieva J
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy.
Lung Cancer. 2018 Mar;117:64-69.
 18. Spallarossa P, Meliota G, Brunelli C, Arboscello E, Ameri P, Dessalvi CC, **Grossi F**, Deidda M, Mele D, Sarocchi M, Bellodi A, Madonna R, Mercurio G.
Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects.
Med Res Rev. 2018 Sep;38(5):1447-1468. doi: 10.1002/med.21478. Epub 2017 Dec 28. Review.
 19. Genova C, Rijavec E, **Grossi F**.
Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: can we use enemy territory at our advantage?
J Thorac Dis. 2017 Nov;9(11):4300-4304.
 20. Truini A, Coco S, Nadal E, Genova C, Mora M, Dal Bello MG, Vanni I, Alama A, Rijavec E, Biello F, Barletta G, Merlo DF, Valentino A, Ferro P, Ravetti GL, Stigliani S, Viganì A, Fedeli F, Beer DG, Roncella S, **Grossi F**
Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma.
Oncotarget. 2017 Aug 2;8(40):68627-68640.
 21. Alama A, Coco S, Vanni I, **Grossi F**.
Reply to the Letter to the Editor by C. Nicolazzo et al.: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated

- with First-Line Chemotherapy".
Int J Mol Sci. 2017 Jun 19;18(6).
22. Dal Bello MG, Alama A, Coco S, Vanni I, **Grossi F**.
Understanding the checkpoint blockade in lung cancer immunotherapy.
Drug Discov Today. 2017 Jun 7. pii: S1359-6446(17)30299-4.
 23. Vanni I, Alama A, **Grossi F**, Dal Bello MG, Coco S.
Exosomes: a new horizon in lung cancer.
Drug Discov Today. 2017 Jun;22(6):927-936.
 24. Coco S, Alama A, Vanni I, Fontana V, Genova C, Dal Bello MG, Truini A, Rijavec E, Biello F, Sini C, Burrafato G, Maggioni C, Barletta G, **Grossi F**.
 25. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line.Chemotherapy.
Int J Mol Sci. 2017 May 11;18(5).
 26. Genova C, Rossi G, Rijavec E, Biello F, Barletta G, Tagliamento M, **Grossi F**.
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer.
Expert Opin Drug Saf. 2017 Apr 19:1-13.
 27. Rijavec E, Genova C, Barletta G, Biello F, Rossi G, Tagliamento M, Dal Bello MG, Coco S, Vanni I, Boccardo S, Alama A, **Grossi F**.
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.
Expert Opin Investig Drugs. 2017 May;26(5):551-561.
 28. Morbelli S, Alama A, Ferrarazzo G, Coco S, Genova C, Rijavec E, Bongioanni F, Biello F, Dal Bello MG, Barletta G, Massollo M, Vanni I, Piva R, Nieri A, Bauckneht M, Sambuceti G, **Grossi F**.
Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): an (18)F-FDG PET/CT study.
J Nucl Med. 2017 Apr 27. pii: jnumed.117.193201.
 29. Tiseo M, Boni L, Ambrosio F, Camerini A, Baldini E, Cinieri S, Brighenti M, Zanelli F, Defraia E, Chiari R, Dazzi C, Tibaldi C, Turolla GM, D'Alessandro V, Zilembo N, Trolese AR, **Grossi F**, Riccardi F, Ardizzoni A.
Italian, Multicenter Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.
J Clin Oncol. 2017 Apr 20;35(12):1281-1287.
 30. Bauckneht M, Piva R, Sambuceti G, **Grossi F**, Morbelli S. Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?
World J Radiol. 2017 Feb 28;9(2):27-33.
 31. **Grossi F**, Rijavec E, Genova C, Barletta G, Biello F, Maggioni C, Burrafato G, Sini C, Dal Bello MG, Meyer K, Roder J, Roder H, Grigorieva J.
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.
Br J Cancer. 2017 Jan 3;116(1):36-43.
 32. Genova C, Rijavec E, Biello F, Rossi G, Barletta G, Dal Bello MG, Vanni I, Coco S, Alama A, **Grossi F**.
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer.
Expert Opin Pharmacother. 2017 Jan;18(1):19-33.
 33. Genova C, Alama A, Coco S, Rijavec E, Dal Bello MG, Vanni I, Biello F, Barletta G, Rossi G, **Grossi F**.
Vinflunine for the treatment of non-small cell lung cancer.
Expert Opin Investig Drugs. 2016 Dec;25(12):1447-1455.

34. **Grossi F.**
New perspectives in second-line treatment in non-squamous non-small cell lung cancer.
Recenti Prog Med. 2016 Dec;107(12):641-646.
35. Vanni I, Coco S, Bonfiglio S, Cittaro D, Genova C, Biello F, Mora M, Rossella V, Dal Bello MG, Truini A, Banelli B, Lazarevic D, Alama A, Rijavec E, Barletta G, **Grossi F.**
Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report.
Medicine (Baltimore). 2016 Nov;95(48):e5447.
36. Ardizzoni A, Tiseo M, Boni L, Di Maio M, Buffoni L, Belvedere O, **Grossi F.** D'Alessandro V, de Marinis F, Barbera S, Caroti C, Favaretto A, Cortinovis D, Morrica B, Tixi L, Ceschia T, Parisi S, Ricardi U, Grimaldi A, Loreggian L, Navarria P, Huber RM, Belani C, Bruswig PF, Scagliotti GV, Sclaro T.
Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC.
Lung Cancer. 2016 Oct;100:30-7.
37. **Grossi F.** Bennouna J, Havel L, Hochmair M, Almodovar T.
Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries.
Curr Med Res Opin. 2016 Sep;32(9):1577-84.
38. Bonfiglio S, Vanni I, Rossella V, Truini A, Lazarevic D, Dal Bello MG, Alama A, Mora M, Rijavec E, Genova C, Cittaro D, **Grossi F.** Coco S.
Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples.
BMC Cancer. 2016 Aug 30;16:692.
39. Maggioni C, Barletta G, Rijavec E, Biello F, Gualco E, **Grossi F.**
Advances in treatment of mesothelioma.
Expert Opin Pharmacother. 2016 Jun;17(9):1197-205.
40. Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, **Grossi F.** Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D; LUX-Lung 5 Investigators.
Afinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Ann Oncol. 2016 Mar;27(3):417-23.
41. Genova C, Rijavec E, **Grossi F.**
Hematopoietic growth factors in lung cancer.
Curr Opin Oncol. 2016 Mar;28(2):135-44.
42. Biello F, Burrafato G, Rijavec E, Genova C, Barletta G, Truini A, Coco S, Dal Bello MG, Alama A, Boccardo F, **Grossi F.**
Fibroblast Growth Factor Receptor (FGFR): A new target for non-small cell lung cancer therapy.
Anticancer Agents Med Chem. 2016;16(9):1142-54.
43. Genova C, Rijavec E, **Grossi F.**
Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers.
Expert Rev Anticancer Ther. 2016;16(1):1-4.
44. Truini A, Coco S, Genova C, Mora M, Dal Bello MG, Vanni I, Alama A, Rijavec E, Barletta G, Biello F, Maggioni C, **Grossi F.**
Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.
Microna. 2016;5(1):12-18.
45. Dal Bello MG, Alama A, Barletta G, Coco S, Truini A, Vanni I, Boccardo S, Genova C, Rijavec E, Biello F, Bottoni G, Sambuceti G, **Grossi F.**
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors.

- Int J Cancer. 2015 Dec 15;137(12):2947-58.
46. Vanni I, Coco S, Truini A, Rusmini M, Dal Bello MG, Alama A, Banelli B, Mora M, Rijavec E, Barletta G, Genova C, Biello F, Maggioni C, **Grossi F**.
Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform.
Int J Mol Sci. 2015 Dec 3;16(12):28765-82.
 47. Vansteenkiste JF, Canon JL, Braud FD, **Grossi F**, De Pas T, Gray JE, Su WC, Felip E, Yoshioka H, Gridelli C, Dy GK, Thongprasert S, Reck M, Aimone P, Vidam GA, Roussou P, Wang YA, Di Tomaso E, Soria JC.
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
J Thorac Oncol. 2015 Sep;10(9):1319-27.
 48. Coco S, Truini A, Alama A, Dal Bello MG, Venè R, Garuti A, Carminati E, Rijavec E, Genova C, Barletta G, Sini C, Ballestrero A, Boccardo F, **Grossi F**.
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.
Target Oncol. 2015 Sep;10(3):393-404.
 49. Alama A, Gangemi R, Ferrini S, Barisione G, Orengo AM, Truini M, Bello MG, **Grossi F**.
CD133-Positive Cells from Non-Small Cell Lung Cancer Show Distinct Sensitivity to Cisplatin and Afatinib.
Arch Immunol Ther Exp (Warsz). 2015 Jun;63(3):207-14.
 50. Coco S, Truini A, Vanni I, Genova C, Rosano C, Dal Bello MG, Alama A, Venè R, Rijavec E, Barletta G, Biello F, Boccardo F, **Grossi F**.
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma.
J Thorac Oncol. 2015 Jun;10(6):e50-2.
 51. Cappuzzo F, Finocchiaro G, **Grossi F**, Bidoli P, Favaretto A, Marchetti A, Valente ML, Cseh A, Clementi L, Massey D, Santoro A.
Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.
J Thorac Oncol. 2015 Apr;10(4):665-72.
 52. Coco S, Truini A, Vanni I, Dal Bello MG, Alama A, Rijavec E, Genova C, Barletta G, Sini C, Burrafato G, Biello F, Boccardo F, **Grossi F**.
Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine.
Curr Drug Targets. 2015;16(1):47-59.
 53. **Grossi F**, Dal Bello MG, Salvi S, Puzone R, Pfeffer U, Fontana V, Alama A, Rijavec E, Barletta G, Genova C, Sini C, Ratto GB, Taviani M, Truini M, Merlo DF.
Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.
Dis Markers. 2015;2015:302649.
 54. Rijavec E, Biello F, Genova C, Barletta G, Maggioni C, Dal Bello MG, Coco S, Truini A, Vanni I, Alama A, Beltramini S, Grassi MA, Boccardo F, **Grossi F**.
Belagenpumab+uceL-L for the treatment of non-small cell lung cancer.
Expert Opin Biol Ther. 2015;15(9):1371-9.
 55. Genova C, Rijavec E, **Grossi F**.
Looking for results in non-small-cell lung cancer: is bio-chemotherapy the right answer?
Curr Med Res Opin. 2014 Jul 11:1-3.
 56. Natale R, Blackhall F, Kowalski D, Ramlau R, Beppler G, **Grossi F**, Lerchenmüller C, Pinder Schenck M, Mezger J, Danson S, Gadgeel SM, Summers Y, Callies S, André V, Das M, Lahn M, Talbot D.
Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study.
J Thorac Oncol. 2014 Nov;9(11):1704-8.

57. Aprile G, Rijavec E, Fontanella C, Rihawi K, **Grossi F**.
Ramucirumab: preclinical research and clinical development.
Onco Targets Ther. 2014 Oct 29;7:1997-2006.
58. Alama A, Truini A, Coco S, Genova C, **Grossi F**.
Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer.
Drug Discov Today. 2014 Oct;19(10):1671-6.
59. Genestreti G, **Grossi F**, Genova C, Burgio MA, Bongiovanni A, Gavelli G, Bartolotti M, Di Battista M, Cavallo G, Brandes AA.
Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview.
Future Oncol. 2014 Oct;10(13):2081-96.
60. Gridelli C, de Marinis F, Ardizzoni A, Novello S, Fontanini G, Cappuzzo F, **Grossi F**, Santo A, Cortinovis D, Favaretto A, Lorusso V, Galetta D, Siena S, Bettini A, Iurlaro M, Caprioli A; on behalf of LIFE study team.
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.
J Cancer Res Clin Oncol. 2014 Oct;140(10):1783-93.
61. Truini A, Alama A, Dal Bello MG, Coco S, Vanni I, Rijavec E, Genova C, Barletta G, Biello F, **Grossi F**.
Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System.
Front Oncol. 2014 Sep 4;4:242.
62. de Marinis F, Ardizzoni A, Fontanini G, **Grossi F**, Cappuzzo F, Novello S, Santo A, Lorusso V, Cortinovis D, Iurlaro M, Galetta D, Gridelli C; LIFE study team.
Management of Italian Patients With Advanced Non-Small-Cell Lung Cancer After Second-Line Treatment: Results of the Longitudinal Phase of the LIFE Observational Study.
Clin Lung Cancer. 2014 Sep;15(5):338-45.
63. Truini A, Coco S, Alama A, Genova C, Sini C, Dal Bello MG, Barletta G, Rijavec E, Burrafato G, Boccardo F, **Grossi F**.
Role of microRNAs in malignant mesothelioma.
Cell Mol Life Sci. 2014 Aug;71(15):2865-78.
64. Rijavec E, Genova C, Barletta G, Biello F, Dal Bello MG, Coco S, Truini A, Vanni I, Alama A, Boccardo F, **Grossi F**.
Efficacy of motesanib diphosphate in non-small-cell lung cancer.
Expert Opin Pharmacother. 2014 Aug;15(12):1771-80.
65. Barletta G, Genova C, Rijavec E, Burrafato G, Biello F, Sini C, Dal Bello MG, Coco S, Truini A, Vanni I, Alama A, Beltramini S, Grassi MA, Boccardo F, **Grossi F**.
Oral vinorelbine in the treatment of non-small-cell lung cancer.
Expert Opin Pharmacother. 2014 Aug;15(11):1585-99.
66. von Pawel J, Gorbounova V, Reck M, Kowalski DM, Allard A, Chadjaa M, Rey A, Bennouna J, **Grossi F**; DISRUPT Investigators.
DISRUPT: A randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer.
Lung Cancer. 2014 Aug;85(2):224-9.
67. Rijavec E, Genova C, Barletta G, Burrafato G, Biello F, Dal Bello MG, Coco S, Truini A, Alama A, Boccardo F, **Grossi F**.
Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy.
Expert Opin Biol Ther. 2014 Jul;14(7):1007-17.
68. Gregorc V, Novello S, Lazzari C, Barni S, Aieta M, Mencoboni M, **Grossi F**, Pas TD, de Marinis F, Bearz A, Floriani I, Torri V, Bulotta A, Cattaneo A, Grigorieva J, Tsy-pin M, Roder J, Doglioni C, Levra MG, Petrelli F, Foti S, Viganò M, Bachi A, Roder H.

69. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.
Lancet Oncol. 2014 Jun;15(7):713-21.
70. Gridelli C, Novello S, Zilembo N, Luciani A, Favaretto AG, De Marinis F, Genestreti G, Crinò L, **Grossi F**, Caffo O, Ferrà F, Cruciani G, Brandes AA, Galetta D, Barni S, Fasola G, Cerea G, Ferrari S, Iannacone C, Ciardiello F.
Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Elderly Patients.
J Thorac Oncol. 2014 May;9(5):733-7.
71. Genova C, Rijavec E, Barletta G, Burrafato G, Biello F, Dal Bello MG, Coco S, Truini A, Alama A, Boccardo F, **Grossi F**.
Afinib for the treatment of advanced non-small-cell lung cancer.
Expert Opin Pharmacother. 2014 Apr;15(6):889-903.
72. Rijavec E, Genova C, Alama A, Barletta G, Sini C, Pronzato P, Coco S, Bello MG, Savarino G, Truini A, Boccardo F, **Grossi F**.
Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.
Future Oncol. 2014 Jan;10(1):79-90.
73. Groen HJ, Socinski MA, **Grossi F**, Juhasz E, Gridelli C, Baas P, Butts CA, Chmielowska E, Usari T, Selaru P, Harmon C, Williams JA, Gao F, Tye L, Chao RC, Blumenschein GR Jr.
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).
Ann Oncol. 2013 Sep;24(9):2382-9.
74. O'Brien ME, Gaafar RM, Popat S, **Grossi F**, Price A, Talbot DC, Cufer T, Ottensmeier C, Danson S, Pallis A, Hasan B, Van Meerbeeck JP, Baas P.
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
Eur J Cancer. 2013 Sep;49(13):2815-22.
75. Puzone R, Savarino G, Salvi S, Dal Bello MG, Barletta G, Genova C, Rijavec E, Sini C, Esposito AI, Ratto GB, Truini M, **Grossi F**, Pfeffer U.
Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients.
Mol Cancer. 2013 Aug 29;12(1):97.
76. Ceresoli GL, Zucali PA, Mencoboni M, Botta M, **Grossi F**, Cortinovis D, Zilembo N, Ripa C, Tiseo M, Favaretto AG, Soto-Parra H, De Vincenzo F, Bruzzone A, Lorenzi E, Gianoncelli L, Ercoli B, Giordano L, Santoro A.
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.
Br J Cancer. 2013 Aug 6;109(3):552-8.
77. Genova C, Rijavec E, Truini A, Coco S, Sini C, Barletta G, Dal Bello MG, Alama A, Savarino G, Pronzato P, Boccardo F, **Grossi F**.
Pemetrexed for the treatment of non-small cell lung cancer.
Expert Opin Pharmacother. 2013 Aug;14(11):1545-58.
78. **Grossi F**, Genova C, Gaitan ND, Dal Bello MG, Rijavec E, Barletta G, Sini C, Donato C, Beltramini S, Pronzato P, Porcile G, Boccardo F, Walzer S.
Free drugs in clinical trials and their potential cost saving impact on the National Health Service: A retrospective cost analysis in Italy.
Lung Cancer. 2013 Aug;81(2):236-40.

79. Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, **Grossi F**, Recchia F, Zanelli F, Fontanini G, Naldi N, Campanini N, Azzoni C, Bordi C, Ardizzoni A.
Bio-FAST trial group. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.
Br J Cancer. 2013 Apr 30;108(8):1695-703.
80. Sconfienza LM, Mauri G, **Grossi F**, Truini M, Serafini G, Sardanelli F, Murolo C.
Pleural and Peripheral Lung Lesions: Comparison of US- and CT-guided Biopsy.
Radiology. 2013 Mar;266(3):930-5.
81. Salvi S, Fontana V, Boccardo S, Merlo DF, Margallo E, Laurent S, Morabito A, Rijavec E, Dal Bello MG, Mora M, Ratto GB, **Grossi F**, Truini M, Pistillo MP.
Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer.
Cancer Immunol Immunother. 2012 Sep;61(9):1463-72.
82. Genova C, Rijavec E, Barletta G, Sini C, Dal Bello MG, Truini M, Murolo C, Pronzato P, **Grossi F**.
Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer.
Expert Opin Biol Ther. 2012 Jul;12(7):939-48.
83. **Grossi F**.
Management of non-small cell lung in cancer patients with stable disease.
Drugs. 2012 Jun 19;72 Suppl 1:20-7.
84. **Grossi F**, Rijavec E, Dal Bello MG, Defferrari C, Brianti A, Barletta G, Genova C, Murolo C, Cosso M, Fontanini G, Boldrini L, Truini M, Pronzato P.
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.
Cancer Chemother Pharmacol. 2012 Jun;69(6):1407-12.
85. Nuijten MJ, de Castro Carpeño J, Chouaid C, Vergnenègre A, **Grossi F**, Bischoff H, Heigener D, Walzer S.
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
Lung Cancer. 2012 Jun;76(3):465-71.
86. Boni C, Tiseo M, Boni L, Baldini E, Recchia F, Barone C, **Grossi F**, Germano D, Matano E, Marini G, Labianca R, Di Costanzo F, Bagnulo A, Pennucci C, Caroti C, Mencoboni M, Zanelli F, Prochilo T, Cafferata MA, Ardizzoni A.
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).
Br J Cancer. 2012 Feb 14;106(4):658-65.
87. **Grossi F**, de Marinis F, Gebbia V, Riccardi F, Caffo O, Gamucci T, Ferrà F, Nardi M, Moscetti L, Boni L, Dondi D, Galligioni E.
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
Cancer Chemother Pharmacol. 2012 Feb;69(2):369-75.
88. Vergnenègre A, Ray JA, Chouaid C, **Grossi F**, Bischoff HG, Heigener DF, Walzer F.
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer.
Clinicoecon Outcomes Res. 2012;4:31-7.
89. Bello C, Dal Bello G, Cea M, Nahimana A, Aubry D, Garuti A, Motta G, Moran E, Fruscione F, Pronzato P, **Grossi F**, Patrone F, Ballestrero A, Dupuis M, Sordat B, Zimmermann K, Loretan J, Wartmann M, Duchosal MA, Nencioni A, Vogel P.
Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols.
Bioorg Med Chem 2011 Dec 15;19(24):7720-7.

90. Gridelli C, Bennouna J, de Castro J, Dingemans AM, Griesinger F, **Grossi F**, Rossi A, Thatcher N, Wong EK, Langer C.
Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial.
Clin Lung Cancer. 2011 Nov;12(6):407-11.
91. Novello S, Camps C, **Grossi F**, Mazieres J, Abrey L, Vernejoux JM, Thall A, Patyna S, Usari T, Wang Z, Chao RC, Scagliotti G.
Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases.
J Thorac Oncol. 2011 Jul;6(7):1260-6.
92. Banz K, Bischoff H, Brunner M, Chouaid C, de Castro Carpeño J, de Marinis F, **Grossi F**, Vergnenègre A, Walzer S.
Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain.
Lung Cancer. 2011 Dec;74(3):529-34.
93. Belvedere O, Follador A, Rossetto C, Merlo V, Defferrari C, Sibau AM, Aita M, Dal Bello MG, Meduri S, Gaiardo M, Fasola G, **Grossi F**.
A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019).
Eur J Cancer. 2011 Jul;47(11):1653-9.
94. **Grossi F**, Kubota K, Cappuzzo F, de Marinis F, Gridelli C, Aita M, Douillard JY.
Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.
Oncologist. 2010;15(10):1102-12.
95. Giuliani G, **Grossi F**, de Marinis F, Walzer S.
Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy.
Lung Cancer. 2010 Aug;69 Suppl 1:S11-7. Erratum in: Lung Cancer. 2010 Aug;69 Suppl 1:S32.
96. **Grossi F**, Spizzo R, Bordo D, Cacitti V, Valent F, Rossetto C, Follador A, Di Terlizzi S, Aita M, Morelli A, Fasola G, Consiglieri C, Ceschia T, Beltrami CA, Belvedere O.
Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data: An Alpe Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 014).
J Thorac Oncol. 2010 Sep;5(9):1354-1360.
97. Scagliotti G, Novello, von Pawel JS, Reck M, Rodrigues Pereira J, Thomas M, Abrão Miziara JE, Balint B, De Marinis F, Keller K, Arén O, Csollak M, Albert I, Barrios CE, **Grossi F**, Krzakowski M, Cupit L, Cihon F, DiMatteo S, and Hanna N.
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol. 2010 Apr 10;28(11):1835-42.
98. Borcard F, Baud M, Bello C, Dal Bello G, **Grossi F**, Pronzato P, Cea M, Nencioni A, Vogel P.
Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory activity
Bioorg Med Chem Lett. 2010 Sep 1;20(17):5353-6.
99. Bello C, Cea M, Dal Bello G, Garuti A, Rocco I, Cirmena G, Moran E, Nahimana A, Duchosal MA, Fruscione F, Pronzato P, **Grossi F**, Patrone F, Ballestrero A, Dupuis M, Sordat B, Nencioni A, Vogel P.
Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as α -mannosidase inhibitors and with antitumor activities against hematological and solid malignancies.
Bioorg Med Chem. 2010 May 1;18(9):3320-34.

100. Airoidi I, Di Carlo E, Cocco C, Caci E, Cilli M, Sorrentino C, Sozzi G, Ferrini S, Rosini S, Bertolini G, Truini M, **Grossi F**, Galiotta LJ, Ribatti D, Pistoia V.
IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions.
PLoS One. 2009 Jul 1;4(7):e6119.
101. Rotondo R, Barisione G, Mastracci L, **Grossi F**, Orengo AM, Costa R, Truini M, Fabbi M, Ferrini S, Barbieri O.
IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer.
Int J Cancer. 2009 Aug 15;125(4):887-93.
102. **Grossi F**, Aita M, Defferrari C, Rosetti F, Brianti A, Fasola G, Vinante O, Pronzato P, Pappagallo G.
Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach.
Oncologist. 2009 May;14(5):497-510.
103. Tiseo M, Gridelli C, Cascinu S, Crinò L, Piantedosi FV, **Grossi F**, Brandes AA, Labianca R, Siena S, Amoroso D, Belvedere O, Valentino B, Bearz A, Venturino P, Ardizzoni A.
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy.
Lung Cancer. 2009 May;64(2):199-206.
104. **Grossi F**, de Marinis F, Frontini L, Gridelli C.
The dilemma of first-line chemotherapy in advanced non-small-cell lung cancer: are third-generation drugs all the same?
Tumori. 2008 May-Jun;94(3):5-14.
105. Aita M, Fasola G, Defferrari C, Brianti A, Dal Bello MG, Follador A, Sinaccio G, Pronzato P, **Grossi F**.
Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Crit Rev Oncol Hematol. 2008 Dec;68(3):183-96.
106. Ceresoli GL, Castagneto B, Zucali PA, Favaretto A, Mencoboni M, **Grossi F**, Cortinovis D, Del Conte G, Ceribelli A, Bearz A, Salamina S, De Vincenzo F, Cappuzzo F, Marangolo M, Torri V, Santoro A.
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
Br J Cancer. 2008 Jul 8;99(1):51-6.
107. Rotondo R, Mastracci L, Piazza T, Barisione G, Fabbi M, Cassanello M, Costa R, Morandi B, Astigiano S, Cesario A, Sormani MP, Ferlazzo G, **Grossi F**, Ratto GB, Ferrini S, Frumento G.
Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression.
Int J Cancer. 2008 Sep 1;123(5):1108-16.
108. Tiseo M, Ardizzoni A, Cafferata MA, Loprevite M, Chiaramondia M, Filiberti R, Marroni P, **Grossi F**, Paganuzzi M.
Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer.
Anticancer Res. 2008 Jan-Feb;28(1B):507-13.
109. de Marinis F, **Grossi F**.
Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.
Oncologist. 2008;13 Suppl 1:14-20.
110. **Grossi F**, Gridelli C, Aita M, De Marinis F.
Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer.
Crit Rev Oncol Hematol. 2008 Jul;67(1):16-26.
111. Gridelli C, Maione P, Amoroso D, Baldari M, Bearz A, Bettoli V, Cammilluzzi E, Crinò L, De Marinis F, Di Pietro FA, **Grossi F**, Innocenzi D, Micali G, Piantedosi FV, Scartozzi M.
Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.

- Crit Rev Oncol Hematol. 2008 May;66(2):155-62.
112. Loprevite M, Tiseo M, Chiramondia M, Capelletti M, Bozzetti C, Bortesi B, Naldi N, Nizzoli R, Dadati P, Kunkl A, Zennaro D, Lagrasta C, Campanini N, Spiritelli E, Camisa R, **Grossi F**, Rindi G, Franciosi V, Ardizzoni A.
Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.
Clin Cancer Res. 2007 Nov 1;13(21):6518-26.
113. Fasola G, Belvedere O, Aita M, Zanin T, Follador A, Cassetti P, Meduri S, De Pangher V, Pignata G, Rosolen V, Barbone F, **Grossi F**.
Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial - an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002).
Oncologist. 2007 Oct;12(10):1215-24.
114. **Grossi F**, Aita M.
Bevacizumab and non-small-cell lung cancer: starving the enemy to survive.
Expert Opin Biol Ther. 2007 Jul;7(7):1107-19.
115. Gridelli C, Ferrara C, Guerriero C, Palazzo S, Grasso G, Pavese I, Satta F, Bajetta E, Cortinovis D, Barbieri F, Gebbia V, **Grossi F**, Novello S, Baldini E, Gasparini G, Latino W, Durante E, Giustini L, Negrini C.
Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study.
J Thorac Oncol. 2007 Jun;2(6):475-80. Erratum in: J Thorac Oncol. 2007 Jul;2(7):676.
116. **Grossi F**, Aita M, Follador A, Defferrari C, Brianti A, Sinaccio G, Belvedere O.
Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature.
Oncologist. 2007 Apr;12(4):451-64.
117. Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, **Grossi F**, Paganuzzi M.
Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
Cancer. 2006 Dec 15;107(12):2842-9.
118. **Grossi F**, Tiseo M.
Granulocyte growth factors in the treatment of non-small cell lung cancer(NSCLC).
Crit Rev Oncol Hematol. 2006 Jun;58(3):221-30.
119. Rinaldi M, Belvedere O, Cauchi C, Defferrari C, Viola G, **Grossi F**.
Maintenance chemotherapy in non-small cell lung cancer.
Ann Oncol. 2006 Mar;17 Suppl 2:ii67-70.
120. Ceresoli GL, Zucali PA, Favaretto AG, **Grossi F**, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morengi E, Cavina R, Marangolo M, Parra HJ, Santoro A.
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
J Clin Oncol. 2006 Mar 20;24(9):1443-8.
121. Benasso M, Ponzanelli A, Merlano M, Numico G, Ricci I, Vigo V, **Grossi F**, Amadori D, Cavallo G, Capaccetti B, Taveggia P, Boni L, Rosso R.
Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group.
Acta Oncol. 2006;45(2):168-74.
122. **Grossi F**, Fasola G, Rossetto C, Spizzo R, Meduri S, Sibau A, Vigevani E, Tumolo S, Adami G, Sacco C, Recchia L, Rizzato S, Ceschia T, Belvedere O.
Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007).
Lung Cancer. 2006 Apr;52(1):89-92.

123. Belvedere O, **Grossi F**.
Lung Cancer Highlights from ASCO 2005.
Oncologist. 2006 Jan;11(1):39-50.
124. Tiseo M, Franciosi V, **Grossi F**, Ardizzoni A.
Adjuvant chemotherapy for non-small cell lung cancer: ready for clinical practice?
Eur J Cancer. 2006 Jan;42(1):8-16.
125. Belvedere O, **Grossi F**.
To treat or not to treat advanced non-small-cell lung cancer patients with impaired performance status?
J Clin Oncol. 2005 Oct 1;23(28):7231-2.
126. Loprevite M, Tiseo M, **Grossi F**, Scolaro T, Semino C, Pandolfi A, Favoni R, Ardizzoni A.
In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.
Oncol Res. 2005;15(1):39-48.
127. **Grossi F**, Belvedere O, Fasola G, Ceschia T, Meduri S, Sibau A, Sacco C, Bazzocchi M, Talmassons G, Morelli A, Barbone F, Sobrero A.
Tumor measurements on computed tomographic images of non-small cell lung cancer were similar among cancer professionals from different specialties.
J Clin Epidemiol. 2004 Aug;57(8):804-8.
128. Guglielmi A, Barni S, Zaniboni A, Pella N, Belvedere O, Beretta GD, **Grossi F**, Frontini L, Puglisi F, Labianca R, Sobrero A; Gruppo Italiano Studio Carcinomi Apparato Digerente.
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil.
Br J Cancer. 2004 Oct 18;91(8):1428-33.
129. **Grossi F**, Belvedere O, Fasola G, Barbone F, Rizzato S, Sibau A, Recchia L, Vigevani E, Ceschia T, Morelli A, Guglielmi A, Puglisi F, Follador A, Talmassons G, Sobrero AF.
Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001).
Lung Cancer. 2004 Oct;46(1):99-106.
130. Belvedere O, Minisini A, Ramello M, Sobrero A, **Grossi F**.
Information given to cancer patients on diagnosis, prognosis and treatment: the clinical oncologist's perspective.
Eur J Cancer. 2004 Aug;40(12):1850-4.
131. **Grossi F**, Loprevite M, Chiaramondia M, Ceppa P, Pera C, Ratto GB, Serrano J, Ferrara GB, Costa R, Boni L, Ardizzoni A.
Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers.
Eur J Cancer. 2003 Jun;39(9):1242-50.
132. Baas P, Ardizzoni A, **Grossi F**, Nackaerts K, Numico G, Van Marck E, van de Vijver M, Monetti F, Smid-Geirnaerd MJ, van Zandwijk N, Debruyne C, Legrand C, Giaccone G; EORTC Lung Cancer Group.
The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992).
Eur J Cancer. 2003 Feb;39(3):353-7.
133. **Grossi F**, Belvedere O, Rosso R.
Geography of clinical cancer research publications from 1995 to 1999.
Eur J Cancer. 2003 Jan;39(1):106-11.
134. **Grossi F**, Pennucci MC, Serrano J, Frola C, Mereu C, Scolaro T, Ratto GB, Tixi L, Ardizzoni A.
Phase II study of neoadjuvant chemotherapy in patients with surgically-proven, unresectable stage III

- non-small cell lung cancer.
Anticancer Res. 2002 Nov-Dec;22(6B):3519-24.
135. Loprevite M, Favoni RE, de Cupis A, Pirani P, Pietra G, Bruno S, **Grossi F**, Scolaro T, Ardizzoni A.
Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines.
Lung Cancer. 2001 Jul;33(1):27-39.
136. Sobrero A, Puglisi F, Guglielmi A, Belvedere O, Aprile G, Ramello M, **Grossi F**.
Fatigue: a main component of anemia symptomatology.
Semin Oncol. 2001 Apr;28(2 Suppl 8):15-8.
137. Sobrero A, Guglielmi A, Cirillo M, Recaldin E, Frassinetti GL, Aschele C, Ravaioli A, Testore P, Caroti C, Gallo L, Pessi MA, Cortesi E, Turci D, **Grossi F**, Labianca R.
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
Br J Cancer. 2001 Apr 20;84(8):1023-8.
138. **Grossi F**, Scolaro T, Tixi L, Loprevite M, Ardizzoni A.
The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer.
Crit Rev Oncol Hematol. 2001 Jan;37(1):61-7.
139. Ardizzoni A, **Grossi F**, Salvati F, Silvano G, Santi L.
Managing patients with lung cancer. Common international guidelines must be developed.
BMJ. 2000 Feb 5;320(7231):380.
140. Sobrero A, Zaniboni A, Frassinetti GL, Aschele C, Guglielmi A, Giuliani R, Ravaioli A, Lanfranco C, Caroti C, Arnoldi E, Barni S, Gallo L, Pessi MA, Turci D, Cortesi E, **Grossi F**, Frontini L, Piazza E, Bruzzi P, Labianca R.
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers.
Ann Oncol. 2000 Nov;11(11):1413-20.
141. Ardizzoni A, **Grossi F**.
Update on the treatment of small cell lung cancer (SCLC).
Ann Oncol. 2000;11 Suppl 3:101-8.
142. Sobrero A, Guglielmi A, **Grossi F**, Puglisi F, Aschele C.
Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy.
Semin Oncol. 2000 Oct;27(5 Suppl 10):72-7.
143. Sobrero A, **Grossi F**, Guglielmi A.
Role of oxaliplatin in the treatment of colorectal neoplasms.
Tumori. 2000 May-Jun;86(3 Suppl):S3-5.
144. Ardizzoni A, Antonelli G, **Grossi F**, Tixi L, Cafferata M, Rosso R.
The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC).
Ann Oncol. 1999;10 Suppl 5:S13-7.
145. Ardizzoni A, **Grossi F**, Scolaro T, Giudici S, Foppiano F, Boni L, Tixi L, Cosso M, Mereu C, Ratto GB, Vitale V, Rosso R.
Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer
Br J Cancer. 1999 Sep;81(2):310-5.
146. Loprevite M, Favoni RE, de Cupis A, Pirani P, Merlo F, **Grossi F**, Ardizzoni A.
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Int J Oncol. 1999 Oct;15(4):787-92.

147. Ardizzoni A, **Grossi F**, Meazza R, Ferrini S.
New perspectives for the pharmacological and biological therapy of small cell lung cancer.
Crit Rev Oncol Hematol. 1999 Jul;31(2):135-45.
148. Ardizzoni A, **Grossi F**, Pennucci MC.
Systemic drug therapy of malignant pleural mesothelioma.
Monaldi Arch Chest Dis. 1998 Apr;53(2):236-40.
149. **Grossi F**, Pennucci MC, Tixi L, Cafferata MA, Ardizzoni A.
Management of malignant pleural effusions.
Drugs. 1998 Jan;55(1):47-58.
150. Loprevite M, Varesco L, Favoni R, Ferrara GB, Moro F, Ottaggio L, Fronza G, Campomenosi P, Abbondandolo A, Cutrona G, Roncella S, Albini A, Aluigi MG, Pozzi S, Pera C, Biticchi R, Gismondi V, **Grossi F**, Pennucci MC, Ardizzoni A.
Analysis of K-ras, p-53, bcl-2 and Rb expression in non-small cell lung cancer (NSCLC) cell lines.
Int J Oncol. 1997 11: 1203-1208.
151. **Grossi F**, Sobrero A.
The clinical management of early and advanced colorectal cancer.
Adv Clin Path. 1997 Oct;1(4):261-267.
152. Guglielmi A, Aschele C, **Grossi F**, Tixi L, Sobrero A.
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
Cytotechnology. 1996;19(3):215-9.
153. Melloni E, Pontremoli S, Sparatore B, Patrone M, **Grossi F**, Marks PA, Rifkind RA.
Introduction of the beta isozyme of protein kinase C accelerates induced differentiation of murine erythroleukemia cells.
Proc Natl Acad Sci USA. 1990 Jun;87(12):4417-20.

Altro:

Articoli in inglese non indicizzati in PubMed= 8
Articoli in italiano non indicizzati in PubMed = 9
Capitoli di libri = 12
Abstracts= 295
Meetings report= 15
Altre pubblicazioni = 13

Autorizzo il trattamento dei dati in conformità a quanto previsto dal DL 196/03 e al successivo Regolamento UE 2016/679
Genova, 17 gennaio 2019

